Scandinavian ChemoTech AB Class B (8V6) Stock Price & Analysis

8V6 Stock Chart & Stats

€0.15€0.01(4.05%)

At close: Oct 30 5:30 PM GMT+1

Day’s Range: EUR 0.15 - EUR 0.15
52-Week Range: EUR 0.10 - EUR 0.50
Previous Close: EUR 0.15
Volume: 0
Average Volume (3M): 0
Market Cap: EUR 5.33M
Enterprise Value: EUR 95.90M
Total Cash (Recent Filing): EUR 1.46M
Total Debt (Recent Filing): EUR 0
Price to Earnings (P/E): ―
Beta: -1.39
Next Earnings: Feb 23, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

Rapid TTM revenue expansion indicates growing commercial activity and increasing adoption of the company’s offerings. If this trajectory persists, a larger revenue base could improve operating leverage, support broader market reach, and provide a foundation for eventual profitability.

Improved Gross Margin

The return to a positive gross margin is an important improvement in underlying economics, showing that revenue is generating value after direct costs. Maintaining this level would strengthen the platform for absorbing operating expenses and could make future scale more financially productive.

Debt-Free Balance Sheet

An essentially debt-free balance sheet reduces refinancing exposure and interest-rate sensitivity, preserving financial flexibility while the company develops its business. The absence of debt also gives management more capacity to direct future resources toward operations rather than mandatory debt servicing.

Bears Say

Persistent Unprofitability

Despite strong revenue growth and improved gross margin, operating costs continue to exceed gross profit, leaving the company deeply loss-making. Persistent negative earnings weaken internal funding capacity and make the durability of growth dependent on achieving further cost control and scale.

Negative Free Cash Flow

Continued cash consumption means the business is not yet funding itself through operations, even though the burn rate has improved from earlier periods. Sustained negative free cash flow can constrain investment capacity and increase the importance of future profitability or external funding.

Eroding Equity Base

A shrinking equity base reflects the cumulative effect of ongoing losses and reduces the capital cushion supporting the business. Unless losses narrow, continued erosion could weaken resilience, limit strategic flexibility, and make future growth investment more dependent on raising additional capital.

Scandinavian ChemoTech AB Class B News

Is 8V6 a Buy, Before Earnings?

Scandinavian ChemoTech AB Class B (8V6) is scheduled to report 4th quarter earnings on 03/05/2024. Regarding Q4 estimates, Wall Street analysts expect Scandinavian ChemoTech AB Class B to post earnings

2y ago8V6

8V6 FAQ

What was Scandinavian ChemoTech AB Class B’s price range in the past 12 months?

Scandinavian ChemoTech AB Class B lowest stock price was €0.10 and its highest was €0.50 in the past 12 months.

What is Scandinavian ChemoTech AB Class B’s market cap?

Scandinavian ChemoTech AB Class B’s market cap is €5.33M.

When is Scandinavian ChemoTech AB Class B’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Scandinavian ChemoTech AB Class B’s earnings last quarter?

Scandinavian ChemoTech AB Class B released its earnings results on Oct 27, 2026. The company reported -€0.004 earnings per share for the quarter.

Is Scandinavian ChemoTech AB Class B overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Scandinavian ChemoTech AB Class B pay dividends?

Scandinavian ChemoTech AB Class B does not currently pay dividends.

What is Scandinavian ChemoTech AB Class B’s EPS estimate?

Scandinavian ChemoTech AB Class B’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Scandinavian ChemoTech AB Class B have?

Scandinavian ChemoTech AB Class B has 23,802,313 shares outstanding.

What happened to Scandinavian ChemoTech AB Class B’s price movement after its last earnings report?

Scandinavian ChemoTech AB Class B reported an EPS of -€0.004 in its last earnings report. Following the earnings report the stock price went up 0.585%.

Which hedge fund is a major shareholder of Scandinavian ChemoTech AB Class B?

Currently, no hedge funds are holding shares in DE:8V6

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description